Topical tacrolimus as treatment of atopic dermatitis

Masutaka Furue, Satoshi Takeuchi

研究成果: Contribution to journalReview article査読

2 被引用数 (Scopus)

抄録

Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.

本文言語英語
ページ(範囲)161-166
ページ数6
ジャーナルClinical, Cosmetic and Investigational Dermatology
2
DOI
出版ステータス出版済み - 2009

All Science Journal Classification (ASJC) codes

  • 皮膚病学

フィンガープリント

「Topical tacrolimus as treatment of atopic dermatitis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル